Understanding the Protective Role of Bilirubin in Sepsis Management

Sepsis is a life-threatening condition caused by a dysregulated immune response to infection. Currently, clinicians primarily rely on antibiotics and vasopressors, but mortality rates remain high. New research suggests that bilirubin in sepsis management could offer a novel path for therapeutic intervention. By targeting the underlying mechanisms of tissue injury, this endogenous metabolite may significantly improve patient outcomes.

One of the primary drivers of sepsis-induced damage is the formation of neutrophil extracellular traps (NETs). Although neutrophils use these traps to capture pathogens, excessive NETosis leads to systemic inflammation and organ failure. Therefore, inhibiting this process has become a major focus for scientists looking to develop new sepsis treatments.

Bilirubin Inhibits NOX2-Mediated NETosis

Specifically, a recent study utilized murine models to assess the effects of bilirubin on survival. The researchers found that bilirubin significantly reduced biomarkers of NETosis in the blood. Mechanistically, bilirubin suppresses the activity of NOX2, an enzyme required for reactive oxygen species (ROS) production. Furthermore, it promotes the internalization and degradation of NOX2 through pathways involving autophagy and endocytosis. Consequently, these actions prevent the release of harmful NETs into the system.

In addition, bilirubin demonstrated similar inhibitory effects in human neutrophils. It effectively blocked ROS-dependent NETosis, validating its potential for clinical application. These findings suggest that bilirubin acts as a natural safeguard against the inflammatory storm characteristic of severe infections. Consequently, future therapies may leverage these endogenous pathways to protect against organ dysfunction.

Clinical Implications for Critical Care

Developing new strategies for bilirubin in sepsis management could bridge the gap in current treatment protocols. While high levels of bilirubin are often seen as a marker of liver dysfunction, its physiological role as an antioxidant and anti-inflammatory agent is becoming clearer. Future clinical trials may investigate whether modulating bilirubin levels can provide a protective effect in septic patients.

FAQs

How does bilirubin reduce mortality in sepsis models?

Bilirubin reduces mortality by inhibiting the formation of neutrophil extracellular traps (NETs). These traps are known to cause widespread tissue injury and organ dysfunction during sepsis when released in excess.

What is the specific target of bilirubin in neutrophils?

Bilirubin targets the NOX2 enzyme. It promotes the degradation of NOX2 via endocytosis and autophagy, thereby preventing the oxidative stress necessary for suicidal NETosis.

Can bilirubin be used as a treatment for sepsis?

While experimental models show promise, more clinical research is needed to determine how bilirubin or its derivatives can be safely used as a therapeutic intervention in human sepsis cases.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

• Kim SJ et al. Bilirubin reduces mortality in sepsis models by inhibiting NOX2-mediated formation of neutrophil extracellular traps. Redox Rep. 2026 Dec 31. doi: 10.1080/13510002.2026.2664962. PMID: 42050363.


• Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.


• Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134-147.